A two-cohort phase 1 study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine and erlotinib during radiotherapy for unresectable pancreatic carcinoma

OBJECTIVES: Gemcitabine is a potent radiosensitizer. When combined with standard radiotherapy (XRT) the gemcitabine dose must be reduced to about 10% of its conventional dose. Oxaliplatin and erlotinib also have radiosensitizing properties. In vitro, oxaliplatin and gemcitabine have demonstrated syn...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Raftery, Laura, Tepper, Joel E, Goldberg, Richard M., Blackstock, A. William, Aklilu, Mebea, Bernard, Stephen A., Ivanova, Anastasia, Davies, Janine M., O’Neil, Bert H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3900023/
https://ncbi.nlm.nih.gov/pubmed/22547007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3182467f22
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky